This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-32-5p | ABI3BP | 0 | 0 | 0 | 0 | miRNATAP | -0.45 | 0 | NA | |
2 | hsa-miR-32-5p | ABLIM1 | 0 | 0 | 0 | 0 | mirMAP | -0.22 | 0 | NA | |
3 | hsa-miR-32-5p | ACACB | 0 | 0 | 0 | 0 | mirMAP | -0.59 | 0 | NA | |
4 | hsa-miR-32-5p | ACTC1 | 0 | 0 | 0 | 0 | MirTarget | -0.22 | 0.00254 | NA | |
5 | hsa-miR-32-5p | ADAM10 | 0 | 0 | 0 | 0 | MirTarget | -0.15 | 0 | NA | |
6 | hsa-miR-32-5p | ADAM22 | 0 | 0 | 0 | 0 | mirMAP | -0.33 | 0 | NA | |
7 | hsa-miR-32-5p | ADAM23 | 0 | 0 | 0 | 0 | miRNATAP | -0.25 | 1.0E-5 | NA | |
8 | hsa-miR-32-5p | ADAMTSL1 | 0 | 0 | 0 | 0 | miRNATAP | -0.28 | 0 | NA | |
9 | hsa-miR-32-5p | ADAMTSL3 | 0 | 0 | 0 | 0 | MirTarget; miRNATAP | -0.26 | 0 | NA | |
10 | hsa-miR-32-5p | ADCY1 | 0 | 0 | 0 | 0 | mirMAP | -0.29 | 5.0E-5 | NA | |
11 | hsa-miR-32-5p | ADCY5 | 0 | 0 | 0 | 0 | mirMAP | -0.58 | 0 | NA | |
12 | hsa-miR-32-5p | ADCY9 | 0 | 0 | 0 | 0 | mirMAP | -0.13 | 1.0E-5 | NA | |
13 | hsa-miR-32-5p | ADCYAP1R1 | 0 | 0 | 0 | 0 | mirMAP | -0.77 | 0 | NA | |
14 | hsa-miR-32-5p | ADM | 0 | 0 | 0 | 0 | miRNATAP | -0.22 | 7.0E-5 | NA | |
15 | hsa-miR-32-5p | AFF2 | 0 | 0 | 0 | 0 | mirMAP | -0.27 | 0 | NA | |
16 | hsa-miR-32-5p | AFF3 | 0 | 0 | 0 | 0 | MirTarget | -0.41 | 0 | NA | |
17 | hsa-miR-32-5p | AFF4 | 0 | 0 | 0 | 0 | mirMAP; miRNATAP | -0.16 | 0 | NA | |
18 | hsa-miR-32-5p | AKAP10 | 0 | 0 | 0 | 0 | miRNATAP | -0.15 | 0 | NA | |
19 | hsa-miR-32-5p | AKAP12 | 0 | 0 | 0 | 0 | mirMAP | -0.63 | 0 | NA | |
20 | hsa-miR-32-5p | ALDH1L2 | 0 | 0 | 0 | 0 | mirMAP | -0.1 | 0.01731 | NA | |
21 | hsa-miR-32-5p | ALPK3 | 0 | 0 | 0 | 0 | miRNATAP | -0.24 | 0 | NA | |
22 | hsa-miR-32-5p | ANGPTL2 | 0 | 0 | 0 | 0 | miRNATAP | -0.43 | 0 | NA | |
23 | hsa-miR-32-5p | ANKRD12 | 0 | 0 | 0 | 0 | MirTarget | -0.1 | 6.0E-5 | NA | |
24 | hsa-miR-32-5p | APCDD1L | 0 | 0 | 0 | 0 | mirMAP | -0.35 | 0 | NA | |
25 | hsa-miR-32-5p | ARHGAP24 | 0 | 0 | 0 | 0 | MirTarget | -0.23 | 0 | NA | |
26 | hsa-miR-32-5p | ARHGAP29 | 0 | 0 | 0 | 0 | MirTarget | -0.27 | 0 | NA | |
27 | hsa-miR-32-5p | ARHGEF17 | 0 | 0 | 0 | 0 | miRNATAP | -0.19 | 0 | NA | |
28 | hsa-miR-32-5p | ARL10 | 0 | 0 | 0 | 0 | mirMAP | -0.24 | 0 | NA | |
29 | hsa-miR-32-5p | ARRDC3 | 0 | 0 | 0 | 0 | MirTarget; miRNATAP | -0.21 | 0 | NA | |
30 | hsa-miR-32-5p | ARRDC4 | 0 | 0 | 0 | 0 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.22 | 0 | NA | |
31 | hsa-miR-32-5p | ASB1 | 0 | 0 | 0 | 0 | mirMAP | -0.15 | 0 | NA | |
32 | hsa-miR-32-5p | ATP2B4 | 0 | 0 | 0 | 0 | MirTarget | -0.19 | 0 | NA | |
33 | hsa-miR-32-5p | ATP7A | 0 | 0 | 0 | 0 | miRNATAP | -0.14 | 0 | NA | |
34 | hsa-miR-32-5p | ATP8A2 | 0 | 0 | 0 | 0 | mirMAP | -0.25 | 0.00012 | NA | |
35 | hsa-miR-32-5p | ATP8B1 | 0 | 0 | 0 | 0 | miRNATAP | -0.11 | 0.00287 | NA | |
36 | hsa-miR-32-5p | ATRX | 0 | 0 | 0 | 0 | MirTarget; miRNATAP | -0.14 | 0 | NA | |
37 | hsa-miR-32-5p | ATXN1 | 0 | 0 | 0 | 0 | miRNAWalker2 validate; miRNATAP | -0.13 | 0 | NA | |
38 | hsa-miR-32-5p | ATXN1L | 0 | 0 | 0 | 0 | miRNATAP | -0.15 | 0 | NA | |
39 | hsa-miR-32-5p | B3GALT2 | 0 | 0 | 0 | 0 | MirTarget; miRNATAP | -0.17 | 0.00024 | NA | |
40 | hsa-miR-32-5p | BAZ2B | 0 | 0 | 0 | 0 | miRNATAP | -0.18 | 0 | NA | |
41 | hsa-miR-32-5p | BBX | 0 | 0 | 0 | 0 | mirMAP | -0.12 | 0 | NA | |
42 | hsa-miR-32-5p | BCL2L2 | 0 | 0 | 0 | 0 | mirMAP | -0.14 | 0 | NA | |
43 | hsa-miR-32-5p | BMPR2 | 0 | 0 | 0 | 0 | miRNATAP | -0.17 | 0 | NA | |
44 | hsa-miR-32-5p | BSN | 0 | 0 | 0 | 0 | MirTarget; miRNATAP | -0.13 | 0.00398 | NA | |
45 | hsa-miR-32-5p | BTG2 | 0 | 0 | 0 | 0 | MirTarget; miRNATAP | -0.29 | 0 | 22266859 | Androgen regulated miR 32 targets BTG2 and is overexpressed in castration resistant prostate cancer; In conclusion androgen-regulated miR-32 is overexpressed in CRPC leading to reduced expression of BTG2 |
46 | hsa-miR-32-5p | C1orf64 | 0 | 0 | 0 | 0 | mirMAP | -0.78 | 0 | NA | |
47 | hsa-miR-32-5p | C20orf194 | 0 | 0 | 0 | 0 | miRNATAP | -0.25 | 0 | NA | |
48 | hsa-miR-32-5p | C2CD2 | 0 | 0 | 0 | 0 | mirMAP | -0.21 | 0 | NA | |
49 | hsa-miR-32-5p | C2orf72 | 0 | 0 | 0 | 0 | mirMAP | -0.21 | 0.01171 | NA | |
50 | hsa-miR-32-5p | C6orf120 | 0 | 0 | 0 | 0 | mirMAP | -0.1 | 0 | NA | |
51 | hsa-miR-32-5p | CACNB4 | 0 | 0 | 0 | 0 | mirMAP | -0.3 | 0 | NA | |
52 | hsa-miR-32-5p | CADM2 | 0 | 0 | 0 | 0 | MirTarget; mirMAP; miRNATAP | -0.47 | 0 | NA | |
53 | hsa-miR-32-5p | CALN1 | 0 | 0 | 0 | 0 | miRNATAP | -0.69 | 0 | NA | |
54 | hsa-miR-32-5p | CBLN4 | 0 | 0 | 0 | 0 | MirTarget; miRNATAP | -0.59 | 0 | NA | |
55 | hsa-miR-32-5p | CCDC50 | 0 | 0 | 0 | 0 | mirMAP | -0.16 | 0 | NA | |
56 | hsa-miR-32-5p | CCNJL | 0 | 0 | 0 | 0 | MirTarget; miRNATAP | -0.1 | 0.02581 | NA | |
57 | hsa-miR-32-5p | CDC42BPA | 0 | 0 | 0 | 0 | miRNATAP | -0.17 | 0 | NA | |
58 | hsa-miR-32-5p | CDKN1C | 0 | 0 | 0 | 0 | MirTarget; miRNATAP | -0.3 | 0 | NA | |
59 | hsa-miR-32-5p | CEBPA | 0 | 0 | 0 | 0 | miRNATAP | -0.19 | 0 | NA | |
60 | hsa-miR-32-5p | CELF2 | 0 | 0 | 0 | 0 | miRNATAP | -0.22 | 0 | NA | |
61 | hsa-miR-32-5p | CFL2 | 0 | 0 | 0 | 0 | miRNATAP | -0.22 | 0 | NA | |
62 | hsa-miR-32-5p | CHD9 | 0 | 0 | 0 | 0 | miRNATAP | -0.23 | 0 | NA | |
63 | hsa-miR-32-5p | CHST7 | 0 | 0 | 0 | 0 | MirTarget | -0.1 | 0.00016 | NA | |
64 | hsa-miR-32-5p | CHSY3 | 0 | 0 | 0 | 0 | miRNATAP | -0.16 | 0 | NA | |
65 | hsa-miR-32-5p | CLDN11 | 0 | 0 | 0 | 0 | MirTarget | -0.6 | 0 | NA | |
66 | hsa-miR-32-5p | CNTN1 | 0 | 0 | 0 | 0 | miRNATAP | -0.66 | 0 | NA | |
67 | hsa-miR-32-5p | CNTN4 | 0 | 0 | 0 | 0 | miRNATAP | -0.46 | 0 | NA | |
68 | hsa-miR-32-5p | COL12A1 | 0 | 0 | 0 | 0 | miRNATAP | -0.15 | 0.00211 | NA | |
69 | hsa-miR-32-5p | COL1A2 | 0 | 0 | 0 | 0 | MirTarget; miRNATAP | -0.11 | 0.03098 | NA | |
70 | hsa-miR-32-5p | CPEB1 | 0 | 0 | 0 | 0 | miRNATAP | -0.55 | 0 | NA | |
71 | hsa-miR-32-5p | CPEB2 | 0 | 0 | 0 | 0 | miRNATAP | -0.24 | 0 | NA | |
72 | hsa-miR-32-5p | CPEB3 | 0 | 0 | 0 | 0 | MirTarget; miRNATAP | -0.17 | 0 | NA | |
73 | hsa-miR-32-5p | CPEB4 | 0 | 0 | 0 | 0 | miRNAWalker2 validate; miRNATAP | -0.17 | 0 | NA | |
74 | hsa-miR-32-5p | CPNE8 | 0 | 0 | 0 | 0 | miRNATAP | -0.13 | 0.0007 | NA | |
75 | hsa-miR-32-5p | CREB5 | 0 | 0 | 0 | 0 | miRNAWalker2 validate | -0.33 | 0 | NA | |
76 | hsa-miR-32-5p | CSMD1 | 0 | 0 | 0 | 0 | miRNATAP | -0.5 | 0 | NA | |
77 | hsa-miR-32-5p | CSRNP3 | 0 | 0 | 0 | 0 | mirMAP | -0.59 | 0 | NA | |
78 | hsa-miR-32-5p | CTTNBP2 | 0 | 0 | 0 | 0 | miRNATAP | -0.56 | 0 | NA | |
79 | hsa-miR-32-5p | CXXC5 | 0 | 0 | 0 | 0 | MirTarget | -0.12 | 0.00272 | NA | |
80 | hsa-miR-32-5p | DAAM1 | 0 | 0 | 0 | 0 | miRNATAP | -0.18 | 0 | NA | |
81 | hsa-miR-32-5p | DAB2IP | 0 | 0 | 0 | 0 | MirTarget; miRNATAP | -0.14 | 0 | 26622795 | microRNA 32 induces radioresistance by targeting DAB2IP and regulating autophagy in prostate cancer cells; miR-32 expression was upregulated or overexpressed in PCa and miR-32 inhibited DAB2IP expression through a direct binding site within the DAB2IP 3' untranslated region; More significantly the overexpression of miR-32 and the knockdown of DAB2IP enhanced autophagy in the IR-treated PCa cells; In conclusion these data provide novel insights into the mechanisms governing the regulation of DAB2IP expression by miR-32 and their possible contribution to autophagy and radioresistance in PCa |
82 | hsa-miR-32-5p | DCX | 0 | 0 | 0 | 0 | miRNATAP | -0.24 | 0.02025 | NA | |
83 | hsa-miR-32-5p | DDI2 | 0 | 0 | 0 | 0 | mirMAP | -0.21 | 8.0E-5 | NA | |
84 | hsa-miR-32-5p | DDX3X | 0 | 0 | 0 | 0 | miRNATAP | -0.1 | 0 | NA | |
85 | hsa-miR-32-5p | DENND2C | 0 | 0 | 0 | 0 | mirMAP | -0.27 | 0 | NA | |
86 | hsa-miR-32-5p | DENND5B | 0 | 0 | 0 | 0 | mirMAP | -0.21 | 0 | NA | |
87 | hsa-miR-32-5p | DIO2 | 0 | 0 | 0 | 0 | mirMAP | -0.12 | 0.0263 | NA | |
88 | hsa-miR-32-5p | DKK3 | 0 | 0 | 0 | 0 | MirTarget | -0.37 | 0 | NA | |
89 | hsa-miR-32-5p | DLG2 | 0 | 0 | 0 | 0 | mirMAP | -0.32 | 0 | NA | |
90 | hsa-miR-32-5p | DMXL1 | 0 | 0 | 0 | 0 | MirTarget; miRNATAP | -0.2 | 0 | NA | |
91 | hsa-miR-32-5p | DOCK5 | 0 | 0 | 0 | 0 | MirTarget | -0.12 | 0.00116 | NA | |
92 | hsa-miR-32-5p | DOCK9 | 0 | 0 | 0 | 0 | miRNAWalker2 validate; MirTarget | -0.17 | 0 | NA | |
93 | hsa-miR-32-5p | DOK6 | 0 | 0 | 0 | 0 | mirMAP | -0.3 | 0 | NA | |
94 | hsa-miR-32-5p | DSC3 | 0 | 0 | 0 | 0 | miRNAWalker2 validate | -0.46 | 1.0E-5 | NA | |
95 | hsa-miR-32-5p | DSCAML1 | 0 | 0 | 0 | 0 | MirTarget; miRNATAP | -0.31 | 1.0E-5 | NA | |
96 | hsa-miR-32-5p | DSEL | 0 | 0 | 0 | 0 | mirMAP | -0.45 | 0 | NA | |
97 | hsa-miR-32-5p | DST | 0 | 0 | 0 | 0 | miRNAWalker2 validate; mirMAP | -0.47 | 0 | NA | |
98 | hsa-miR-32-5p | DUSP19 | 0 | 0 | 0 | 0 | mirMAP | -0.11 | 0 | NA | |
99 | hsa-miR-32-5p | EGR2 | 0 | 0 | 0 | 0 | miRNATAP | -0.38 | 0 | NA | |
100 | hsa-miR-32-5p | EIF5A2 | 0 | 0 | 0 | 0 | mirMAP | -0.11 | 0.00024 | NA | |
101 | hsa-miR-32-5p | ESRRG | 0 | 0 | 0 | 0 | miRNATAP | -0.19 | 0.00553 | NA | |
102 | hsa-miR-32-5p | FAM110B | 0 | 0 | 0 | 0 | MirTarget | -0.12 | 0.00428 | NA | |
103 | hsa-miR-32-5p | FAM124A | 0 | 0 | 0 | 0 | mirMAP | -0.12 | 0.00217 | NA | |
104 | hsa-miR-32-5p | FAM135A | 0 | 0 | 0 | 0 | MirTarget; miRNATAP | -0.11 | 0.00339 | NA | |
105 | hsa-miR-32-5p | FAM150B | 0 | 0 | 0 | 0 | MirTarget | -0.28 | 0.00216 | NA | |
106 | hsa-miR-32-5p | FAM160B1 | 0 | 0 | 0 | 0 | miRNATAP | -0.13 | 0 | NA | |
107 | hsa-miR-32-5p | FAM189A1 | 0 | 0 | 0 | 0 | mirMAP | -0.26 | 0.00072 | NA | |
108 | hsa-miR-32-5p | FAM198A | 0 | 0 | 0 | 0 | mirMAP | -0.13 | 0.00859 | NA | |
109 | hsa-miR-32-5p | FAT3 | 0 | 0 | 0 | 0 | mirMAP | -0.56 | 0 | NA | |
110 | hsa-miR-32-5p | FCHO2 | 0 | 0 | 0 | 0 | miRNATAP | -0.16 | 0 | NA | |
111 | hsa-miR-32-5p | FEM1B | 0 | 0 | 0 | 0 | mirMAP | -0.12 | 0 | NA | |
112 | hsa-miR-32-5p | FGF2 | 0 | 0 | 0 | 0 | miRNAWalker2 validate | -0.6 | 0 | NA | |
113 | hsa-miR-32-5p | FHL2 | 0 | 0 | 0 | 0 | miRNATAP | -0.25 | 0 | NA | |
114 | hsa-miR-32-5p | FITM2 | 0 | 0 | 0 | 0 | mirMAP | -0.16 | 0 | NA | |
115 | hsa-miR-32-5p | FLI1 | 0 | 0 | 0 | 0 | miRNATAP | -0.15 | 0 | NA | |
116 | hsa-miR-32-5p | FMN2 | 0 | 0 | 0 | 0 | miRNATAP | -0.41 | 0 | NA | |
117 | hsa-miR-32-5p | FNIP1 | 0 | 0 | 0 | 0 | MirTarget; miRNATAP | -0.16 | 0 | NA | |
118 | hsa-miR-32-5p | FOXN3 | 0 | 0 | 0 | 0 | miRNATAP | -0.25 | 0 | NA | |
119 | hsa-miR-32-5p | FOXP1 | 0 | 0 | 0 | 0 | miRNATAP | -0.12 | 0 | NA | |
120 | hsa-miR-32-5p | FOXP2 | 0 | 0 | 0 | 0 | miRNATAP | -0.52 | 0 | NA | |
121 | hsa-miR-32-5p | FRMPD2 | 0 | 0 | 0 | 0 | mirMAP | -0.57 | 0 | NA | |
122 | hsa-miR-32-5p | FRY | 0 | 0 | 0 | 0 | MirTarget; miRNATAP | -0.34 | 0 | NA | |
123 | hsa-miR-32-5p | FRYL | 0 | 0 | 0 | 0 | miRNATAP | -0.11 | 1.0E-5 | NA | |
124 | hsa-miR-32-5p | FTO | 0 | 0 | 0 | 0 | mirMAP | -0.18 | 0 | NA | |
125 | hsa-miR-32-5p | FYCO1 | 0 | 0 | 0 | 0 | mirMAP | -0.23 | 0 | NA | |
126 | hsa-miR-32-5p | FZD10 | 0 | 0 | 0 | 0 | miRNATAP | -0.12 | 0.01564 | NA | |
127 | hsa-miR-32-5p | FZD4 | 0 | 0 | 0 | 0 | mirMAP | -0.39 | 0 | NA | |
128 | hsa-miR-32-5p | GAP43 | 0 | 0 | 0 | 0 | miRNATAP | -0.2 | 7.0E-5 | NA | |
129 | hsa-miR-32-5p | GATA2 | 0 | 0 | 0 | 0 | MirTarget; miRNATAP | -0.26 | 0 | NA | |
130 | hsa-miR-32-5p | GFPT2 | 0 | 0 | 0 | 0 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.12 | 0.00274 | NA | |
131 | hsa-miR-32-5p | GLCE | 0 | 0 | 0 | 0 | miRNATAP | -0.11 | 0.00026 | NA | |
132 | hsa-miR-32-5p | GLDN | 0 | 0 | 0 | 0 | mirMAP | -0.43 | 0 | NA | |
133 | hsa-miR-32-5p | GLI3 | 0 | 0 | 0 | 0 | mirMAP | -0.29 | 0 | NA | |
134 | hsa-miR-32-5p | GNAQ | 0 | 0 | 0 | 0 | MirTarget | -0.12 | 0 | NA | |
135 | hsa-miR-32-5p | GPC6 | 0 | 0 | 0 | 0 | MirTarget | -0.24 | 1.0E-5 | NA | |
136 | hsa-miR-32-5p | GPRIN2 | 0 | 0 | 0 | 0 | mirMAP | -0.18 | 0.04787 | NA | |
137 | hsa-miR-32-5p | GRAMD3 | 0 | 0 | 0 | 0 | MirTarget; miRNATAP | -0.23 | 0 | NA | |
138 | hsa-miR-32-5p | GRIA3 | 0 | 0 | 0 | 0 | MirTarget; miRNATAP | -0.43 | 0 | NA | |
139 | hsa-miR-32-5p | GRIK3 | 0 | 0 | 0 | 0 | mirMAP | -0.52 | 0 | NA | |
140 | hsa-miR-32-5p | GRK5 | 0 | 0 | 0 | 0 | miRNATAP | -0.17 | 0 | NA | |
141 | hsa-miR-32-5p | GTF2A1 | 0 | 0 | 0 | 0 | MirTarget; miRNATAP | -0.19 | 3.0E-5 | NA | |
142 | hsa-miR-32-5p | HAND2 | 0 | 0 | 0 | 0 | miRNATAP | -0.29 | 0 | NA | |
143 | hsa-miR-32-5p | HAS3 | 0 | 0 | 0 | 0 | miRNATAP | -0.46 | 0 | NA | |
144 | hsa-miR-32-5p | HERC2 | 0 | 0 | 0 | 0 | MirTarget | -0.11 | 0 | NA | |
145 | hsa-miR-32-5p | HFE | 0 | 0 | 0 | 0 | mirMAP | -0.24 | 0 | NA | |
146 | hsa-miR-32-5p | HIPK3 | 0 | 0 | 0 | 0 | MirTarget; miRNATAP | -0.31 | 0 | NA | |
147 | hsa-miR-32-5p | HMBOX1 | 0 | 0 | 0 | 0 | miRNATAP | -0.18 | 0 | NA | |
148 | hsa-miR-32-5p | HOXA9 | 0 | 0 | 0 | 0 | miRNATAP | -0.42 | 0 | NA | |
149 | hsa-miR-32-5p | HOXB8 | 0 | 0 | 0 | 0 | miRNATAP | -0.24 | 3.0E-5 | NA | |
150 | hsa-miR-32-5p | HOXC8 | 0 | 0 | 0 | 0 | miRNATAP | -0.11 | 0.00026 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | NEUROGENESIS | 73 | 1402 | 1.503e-15 | 3.497e-12 |
2 | NEURON DIFFERENTIATION | 56 | 874 | 9.109e-16 | 3.497e-12 |
3 | CELL DEVELOPMENT | 72 | 1426 | 1.179e-14 | 1.828e-11 |
4 | NEURON DEVELOPMENT | 44 | 687 | 1.504e-12 | 1.749e-09 |
5 | CENTRAL NERVOUS SYSTEM DEVELOPMENT | 50 | 872 | 2.482e-12 | 2.309e-09 |
6 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 77 | 1805 | 7.153e-12 | 4.775e-09 |
7 | POSITIVE REGULATION OF GENE EXPRESSION | 75 | 1733 | 7.183e-12 | 4.775e-09 |
8 | HEAD DEVELOPMENT | 43 | 709 | 1.637e-11 | 9.52e-09 |
9 | REGULATION OF CELL DIFFERENTIATION | 67 | 1492 | 2.423e-11 | 1.253e-08 |
10 | FOREBRAIN DEVELOPMENT | 28 | 357 | 2.366e-10 | 1.101e-07 |
11 | NEURON PROJECTION DEVELOPMENT | 35 | 545 | 3.135e-10 | 1.216e-07 |
12 | BEHAVIOR | 34 | 516 | 2.908e-10 | 1.216e-07 |
13 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 69 | 1672 | 4.722e-10 | 1.617e-07 |
14 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 72 | 1784 | 4.866e-10 | 1.617e-07 |
15 | CENTRAL NERVOUS SYSTEM NEURON DEVELOPMENT | 13 | 70 | 5.736e-10 | 1.779e-07 |
16 | RESPONSE TO ENDOGENOUS STIMULUS | 62 | 1450 | 1.082e-09 | 3.146e-07 |
17 | CENTRAL NERVOUS SYSTEM NEURON DIFFERENTIATION | 18 | 166 | 2.725e-09 | 7.46e-07 |
18 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 48 | 1008 | 3.745e-09 | 9.68e-07 |
19 | PALLIUM DEVELOPMENT | 17 | 153 | 5.206e-09 | 1.188e-06 |
20 | NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 50 | 1087 | 5.362e-09 | 1.188e-06 |
21 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 65 | 1618 | 4.852e-09 | 1.188e-06 |
22 | NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 39 | 740 | 8.243e-09 | 1.743e-06 |
23 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 47 | 1004 | 9.442e-09 | 1.91e-06 |
24 | HIPPOCAMPUS DEVELOPMENT | 12 | 73 | 1.138e-08 | 2.206e-06 |
25 | NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 32 | 541 | 1.358e-08 | 2.378e-06 |
26 | NEURON PROJECTION MORPHOGENESIS | 27 | 402 | 1.423e-08 | 2.378e-06 |
27 | TELENCEPHALON DEVELOPMENT | 20 | 228 | 1.431e-08 | 2.378e-06 |
28 | NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 32 | 541 | 1.358e-08 | 2.378e-06 |
29 | NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS | 61 | 1517 | 1.521e-08 | 2.44e-06 |
30 | NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 15 | 126 | 1.632e-08 | 2.531e-06 |
31 | POSITIVE REGULATION OF NEURON DIFFERENTIATION | 23 | 306 | 2.204e-08 | 3.309e-06 |
32 | CELLULAR COMPONENT MORPHOGENESIS | 43 | 900 | 2.392e-08 | 3.478e-06 |
33 | NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 34 | 616 | 2.596e-08 | 3.66e-06 |
34 | NEGATIVE REGULATION OF MOLECULAR FUNCTION | 48 | 1079 | 3.173e-08 | 4.343e-06 |
35 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 60 | 1518 | 3.774e-08 | 5.017e-06 |
36 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 39 | 788 | 4.479e-08 | 5.633e-06 |
37 | CIRCULATORY SYSTEM DEVELOPMENT | 39 | 788 | 4.479e-08 | 5.633e-06 |
38 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 44 | 957 | 4.938e-08 | 5.849e-06 |
39 | NEGATIVE REGULATION OF GENE EXPRESSION | 59 | 1493 | 5.032e-08 | 5.849e-06 |
40 | CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 30 | 513 | 5.052e-08 | 5.849e-06 |
41 | LIMBIC SYSTEM DEVELOPMENT | 13 | 100 | 5.154e-08 | 5.849e-06 |
42 | RESPONSE TO HORMONE | 42 | 893 | 5.471e-08 | 6.061e-06 |
43 | CELLULAR RESPONSE TO HORMONE STIMULUS | 31 | 552 | 7.479e-08 | 8.093e-06 |
44 | REGULATION OF NEURON DIFFERENTIATION | 31 | 554 | 8.109e-08 | 8.575e-06 |
45 | REGULATION OF PROTEIN MODIFICATION PROCESS | 64 | 1710 | 9.318e-08 | 9.635e-06 |
46 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 66 | 1791 | 1.006e-07 | 9.961e-06 |
47 | POSITIVE REGULATION OF NEURON PROJECTION DEVELOPMENT | 19 | 232 | 9.878e-08 | 9.961e-06 |
48 | CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION | 24 | 368 | 1.591e-07 | 1.542e-05 |
49 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 48 | 1142 | 1.755e-07 | 1.667e-05 |
50 | CELL PROJECTION ORGANIZATION | 41 | 902 | 1.99e-07 | 1.852e-05 |
51 | RHYTHMIC PROCESS | 21 | 298 | 2.692e-07 | 2.456e-05 |
52 | INTRACELLULAR SIGNAL TRANSDUCTION | 59 | 1572 | 2.945e-07 | 2.635e-05 |
53 | SINGLE ORGANISM BEHAVIOR | 24 | 384 | 3.465e-07 | 3.042e-05 |
54 | REGULATION OF CELL DEATH | 56 | 1472 | 4.014e-07 | 3.459e-05 |
55 | REGULATION OF HYDROLASE ACTIVITY | 52 | 1327 | 4.53e-07 | 3.833e-05 |
56 | NEGATIVE REGULATION OF CATALYTIC ACTIVITY | 38 | 829 | 4.669e-07 | 3.879e-05 |
57 | EMBRYONIC MORPHOGENESIS | 29 | 539 | 4.859e-07 | 3.966e-05 |
58 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 37 | 799 | 5.222e-07 | 4.189e-05 |
59 | NEGATIVE REGULATION OF PHOSPHORYLATION | 25 | 422 | 5.344e-07 | 4.215e-05 |
60 | REGULATION OF CELL DEVELOPMENT | 38 | 836 | 5.741e-07 | 4.452e-05 |
61 | SKELETAL SYSTEM DEVELOPMENT | 26 | 455 | 6.271e-07 | 4.77e-05 |
62 | REGULATION OF GTPASE ACTIVITY | 33 | 673 | 6.356e-07 | 4.77e-05 |
63 | POSITIVE REGULATION OF AXONOGENESIS | 10 | 69 | 6.514e-07 | 4.811e-05 |
64 | ORGAN MORPHOGENESIS | 38 | 841 | 6.642e-07 | 4.829e-05 |
65 | HEART DEVELOPMENT | 26 | 466 | 9.825e-07 | 7.033e-05 |
66 | POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 25 | 437 | 1.014e-06 | 7.146e-05 |
67 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 37 | 823 | 1.06e-06 | 7.359e-05 |
68 | RESPONSE TO NITROGEN COMPOUND | 38 | 859 | 1.11e-06 | 7.596e-05 |
69 | POSITIVE REGULATION OF CELL DEVELOPMENT | 26 | 472 | 1.247e-06 | 8.409e-05 |
70 | NEGATIVE REGULATION OF KINASE ACTIVITY | 18 | 250 | 1.421e-06 | 9.444e-05 |
71 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 52 | 1381 | 1.496e-06 | 9.723e-05 |
72 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 36 | 801 | 1.504e-06 | 9.723e-05 |
73 | NEGATIVE REGULATION OF CELL DEATH | 38 | 872 | 1.591e-06 | 0.0001014 |
74 | CARDIOCYTE DIFFERENTIATION | 11 | 96 | 1.993e-06 | 0.0001253 |
75 | REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 34 | 750 | 2.472e-06 | 0.0001533 |
76 | MUSCLE STRUCTURE DEVELOPMENT | 24 | 432 | 2.782e-06 | 0.0001703 |
77 | TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 33 | 724 | 3.115e-06 | 0.0001883 |
78 | VASCULATURE DEVELOPMENT | 25 | 469 | 3.587e-06 | 0.000214 |
79 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 25 | 470 | 3.724e-06 | 0.0002193 |
80 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 38 | 905 | 3.815e-06 | 0.0002219 |
81 | REGULATION OF CELLULAR COMPONENT BIOGENESIS | 34 | 767 | 4.02e-06 | 0.0002309 |
82 | CELL PART MORPHOGENESIS | 30 | 633 | 4.137e-06 | 0.000234 |
83 | APPENDAGE DEVELOPMENT | 14 | 169 | 4.224e-06 | 0.000234 |
84 | LIMB DEVELOPMENT | 14 | 169 | 4.224e-06 | 0.000234 |
85 | REGULATION OF TRANSFERASE ACTIVITY | 39 | 946 | 4.358e-06 | 0.0002385 |
86 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 51 | 1395 | 4.427e-06 | 0.0002385 |
87 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 40 | 983 | 4.458e-06 | 0.0002385 |
88 | CEREBRAL CORTEX DEVELOPMENT | 11 | 105 | 4.839e-06 | 0.0002558 |
89 | TISSUE DEVELOPMENT | 54 | 1518 | 4.993e-06 | 0.000261 |
90 | REGULATION OF KINASE ACTIVITY | 34 | 776 | 5.164e-06 | 0.0002645 |
91 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 38 | 917 | 5.174e-06 | 0.0002645 |
92 | NEGATIVE REGULATION OF CELL DIFFERENTIATION | 29 | 609 | 5.487e-06 | 0.0002775 |
93 | POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION | 19 | 303 | 5.58e-06 | 0.0002792 |
94 | CELLULAR RESPONSE TO LIPID | 24 | 457 | 7.234e-06 | 0.0003434 |
95 | EMBRYO DEVELOPMENT | 37 | 894 | 7.132e-06 | 0.0003434 |
96 | TUBE DEVELOPMENT | 27 | 552 | 7.177e-06 | 0.0003434 |
97 | CELL FATE COMMITMENT | 16 | 227 | 7.16e-06 | 0.0003434 |
98 | GLAND DEVELOPMENT | 22 | 395 | 6.971e-06 | 0.0003434 |
99 | EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 27 | 554 | 7.664e-06 | 0.0003602 |
100 | LOCOMOTORY BEHAVIOR | 14 | 181 | 9.343e-06 | 0.0004304 |
101 | CENTRAL NERVOUS SYSTEM NEURON AXONOGENESIS | 6 | 27 | 9.266e-06 | 0.0004304 |
102 | ADULT BEHAVIOR | 12 | 135 | 1.001e-05 | 0.0004567 |
103 | REPRODUCTIVE SYSTEM DEVELOPMENT | 22 | 408 | 1.159e-05 | 0.0005183 |
104 | REGULATION OF NEURON PROJECTION DEVELOPMENT | 22 | 408 | 1.159e-05 | 0.0005183 |
105 | ACTIVATION OF PROTEIN KINASE A ACTIVITY | 5 | 17 | 1.205e-05 | 0.0005341 |
106 | POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 13 | 162 | 1.31e-05 | 0.0005752 |
107 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 52 | 1492 | 1.347e-05 | 0.0005856 |
108 | RESPONSE TO LIPID | 36 | 888 | 1.491e-05 | 0.0006425 |
109 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 43 | 1152 | 1.63e-05 | 0.0006958 |
110 | MUSCLE TISSUE DEVELOPMENT | 17 | 275 | 2.082e-05 | 0.0008806 |
111 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 60 | 1848 | 2.323e-05 | 0.0009738 |
112 | REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 19 | 337 | 2.491e-05 | 0.001035 |
113 | CHEMICAL HOMEOSTASIS | 35 | 874 | 2.541e-05 | 0.001044 |
114 | REGULATION OF CIRCADIAN RHYTHM | 10 | 103 | 2.558e-05 | 0.001044 |
115 | CELLULAR RESPONSE TO ACID CHEMICAL | 13 | 175 | 2.978e-05 | 0.001205 |
116 | NEURON RECOGNITION | 6 | 33 | 3.151e-05 | 0.001264 |
117 | FOREBRAIN GENERATION OF NEURONS | 8 | 66 | 3.337e-05 | 0.001316 |
118 | DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION | 27 | 602 | 3.327e-05 | 0.001316 |
119 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 39 | 1036 | 3.438e-05 | 0.001333 |
120 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 39 | 1036 | 3.438e-05 | 0.001333 |
121 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 24 | 505 | 3.69e-05 | 0.001419 |
122 | NEGATIVE REGULATION OF TRANSFERASE ACTIVITY | 19 | 351 | 4.336e-05 | 0.001654 |
123 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 47 | 1360 | 4.497e-05 | 0.001701 |
124 | CENTRAL NERVOUS SYSTEM PROJECTION NEURON AXONOGENESIS | 5 | 22 | 4.745e-05 | 0.00178 |
125 | POSITIVE REGULATION OF LOCOMOTION | 21 | 420 | 5.507e-05 | 0.002048 |
126 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 38 | 1021 | 5.545e-05 | 0.002048 |
127 | RESPONSE TO ABIOTIC STIMULUS | 38 | 1024 | 5.899e-05 | 0.002161 |
128 | CIRCADIAN RHYTHM | 11 | 137 | 6.006e-05 | 0.002183 |
129 | CARDIAC MUSCLE TISSUE DEVELOPMENT | 11 | 140 | 7.314e-05 | 0.002638 |
130 | REGULATION OF EPITHELIAL CELL MIGRATION | 12 | 166 | 7.807e-05 | 0.002724 |
131 | PERIPHERAL NERVOUS SYSTEM NEURON DIFFERENTIATION | 4 | 13 | 7.845e-05 | 0.002724 |
132 | LOCOMOTION | 40 | 1114 | 7.674e-05 | 0.002724 |
133 | PERIPHERAL NERVOUS SYSTEM NEURON DEVELOPMENT | 4 | 13 | 7.845e-05 | 0.002724 |
134 | REGULATION OF CYTOPLASMIC TRANSLATION | 4 | 13 | 7.845e-05 | 0.002724 |
135 | CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 22 | 465 | 8.293e-05 | 0.002837 |
136 | MOVEMENT OF CELL OR SUBCELLULAR COMPONENT | 44 | 1275 | 8.284e-05 | 0.002837 |
137 | CYCLIC NUCLEOTIDE METABOLIC PROCESS | 7 | 57 | 9.555e-05 | 0.003245 |
138 | IN UTERO EMBRYONIC DEVELOPMENT | 17 | 311 | 9.666e-05 | 0.003259 |
139 | FORELIMB MORPHOGENESIS | 6 | 40 | 9.767e-05 | 0.003269 |
140 | REGULATION OF ACTIN FILAMENT BASED PROCESS | 17 | 312 | 0.0001005 | 0.003316 |
141 | REGULATION OF LIPID METABOLIC PROCESS | 16 | 282 | 0.0001003 | 0.003316 |
142 | LAYER FORMATION IN CEREBRAL CORTEX | 4 | 14 | 0.0001082 | 0.003472 |
143 | MULTICELLULAR ORGANISMAL WATER HOMEOSTASIS | 7 | 58 | 0.0001069 | 0.003472 |
144 | REGULATION OF SYSTEM PROCESS | 23 | 507 | 0.0001076 | 0.003472 |
145 | REGULATION OF CAMP DEPENDENT PROTEIN KINASE ACTIVITY | 4 | 14 | 0.0001082 | 0.003472 |
146 | REGULATION OF LIPID STORAGE | 6 | 41 | 0.0001126 | 0.003589 |
147 | CELL CELL ADHESION VIA PLASMA MEMBRANE ADHESION MOLECULES | 13 | 204 | 0.000143 | 0.004526 |
148 | POSITIVE REGULATION OF EPITHELIAL CELL MIGRATION | 9 | 103 | 0.0001471 | 0.004624 |
149 | BIOLOGICAL ADHESION | 37 | 1032 | 0.0001485 | 0.004636 |
150 | NEGATIVE REGULATION OF LOCOMOTION | 15 | 263 | 0.0001553 | 0.004817 |
151 | NEGATIVE REGULATION OF CELL COMMUNICATION | 41 | 1192 | 0.0001574 | 0.00485 |
152 | REGULATION OF CELLULAR COMPONENT MOVEMENT | 30 | 771 | 0.0001614 | 0.004921 |
153 | HOMOPHILIC CELL ADHESION VIA PLASMA MEMBRANE ADHESION MOLECULES | 11 | 153 | 0.0001618 | 0.004921 |
154 | ODONTOGENESIS | 9 | 105 | 0.0001704 | 0.005148 |
155 | REGULATION OF CELL PROJECTION ORGANIZATION | 24 | 558 | 0.0001715 | 0.005149 |
156 | SEX DIFFERENTIATION | 15 | 266 | 0.0001758 | 0.005243 |
157 | MUSCLE CELL DIFFERENTIATION | 14 | 237 | 0.000178 | 0.005276 |
158 | EPIDERMIS MORPHOGENESIS | 5 | 29 | 0.0001919 | 0.005513 |
159 | POSITIVE REGULATION OF DEVELOPMENTAL GROWTH | 11 | 156 | 0.0001919 | 0.005513 |
160 | RESPONSE TO ARSENIC CONTAINING SUBSTANCE | 5 | 29 | 0.0001919 | 0.005513 |
161 | RESPONSE TO SALT | 4 | 16 | 0.0001909 | 0.005513 |
162 | REGULATION OF FATTY ACID BETA OXIDATION | 4 | 16 | 0.0001909 | 0.005513 |
163 | RESPONSE TO WOUNDING | 24 | 563 | 0.0001958 | 0.00559 |
164 | RESPONSE TO STEROID HORMONE | 22 | 497 | 0.0002138 | 0.006013 |
165 | HORMONE MEDIATED SIGNALING PATHWAY | 11 | 158 | 0.0002145 | 0.006013 |
166 | BLOOD VESSEL MORPHOGENESIS | 18 | 364 | 0.0002128 | 0.006013 |
167 | CYCLIC NUCLEOTIDE MEDIATED SIGNALING | 6 | 46 | 0.0002167 | 0.006037 |
168 | POSITIVE REGULATION OF CELL DEATH | 25 | 605 | 0.0002324 | 0.006437 |
169 | CAMP BIOSYNTHETIC PROCESS | 4 | 17 | 0.0002459 | 0.006692 |
170 | REGULATION OF PRI MIRNA TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 4 | 17 | 0.0002459 | 0.006692 |
171 | NEGATIVE REGULATION OF CELL PROLIFERATION | 26 | 643 | 0.000245 | 0.006692 |
172 | POSITIVE REGULATION OF ENDOTHELIAL CELL MIGRATION | 7 | 67 | 0.0002674 | 0.007192 |
173 | NEURON FATE COMMITMENT | 7 | 67 | 0.0002674 | 0.007192 |
174 | RESPONSE TO PEPTIDE | 19 | 404 | 0.0002703 | 0.007229 |
175 | MUSCLE ORGAN DEVELOPMENT | 15 | 277 | 0.0002722 | 0.007237 |
176 | REGULATION OF BODY FLUID LEVELS | 22 | 506 | 0.0002742 | 0.00725 |
177 | REGULATION OF OSTEOBLAST DIFFERENTIATION | 9 | 112 | 0.0002775 | 0.007296 |
178 | HINDBRAIN DEVELOPMENT | 10 | 137 | 0.0002822 | 0.007337 |
179 | POSITIVE REGULATION OF CAMP METABOLIC PROCESS | 8 | 89 | 0.0002816 | 0.007337 |
180 | RESPONSE TO OXYGEN LEVELS | 16 | 311 | 0.0003054 | 0.007852 |
181 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 25 | 616 | 0.0003045 | 0.007852 |
182 | NEGATIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 5 | 32 | 0.0003107 | 0.007921 |
183 | REGULATION OF B CELL APOPTOTIC PROCESS | 4 | 18 | 0.0003115 | 0.007921 |
184 | REGULATION OF ENDOTHELIAL CELL MIGRATION | 9 | 114 | 0.0003168 | 0.008011 |
185 | WATER HOMEOSTASIS | 7 | 70 | 0.0003512 | 0.008833 |
186 | FEMALE SEX DIFFERENTIATION | 9 | 116 | 0.0003605 | 0.009018 |
187 | REGULATION OF AXONOGENESIS | 11 | 168 | 0.0003643 | 0.009064 |
188 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 51 | 1656 | 0.0003671 | 0.009066 |
189 | REGULATION OF EPITHELIAL CELL PROLIFERATION | 15 | 285 | 0.0003682 | 0.009066 |
190 | RESPIRATORY SYSTEM DEVELOPMENT | 12 | 197 | 0.0003862 | 0.009457 |
191 | RESPONSE TO ACID CHEMICAL | 16 | 319 | 0.0004043 | 0.009848 |
192 | FOREBRAIN NEURON DEVELOPMENT | 5 | 34 | 0.0004162 | 0.009931 |
193 | RENAL WATER HOMEOSTASIS | 5 | 34 | 0.0004162 | 0.009931 |
194 | CAMP METABOLIC PROCESS | 5 | 34 | 0.0004162 | 0.009931 |
195 | REGULATION OF CELL PROLIFERATION | 47 | 1496 | 0.0004114 | 0.009931 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY | 56 | 1199 | 3.232e-10 | 3.003e-07 |
2 | RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING | 37 | 629 | 1.091e-09 | 3.475e-07 |
3 | SEQUENCE SPECIFIC DNA BINDING | 50 | 1037 | 1.122e-09 | 3.475e-07 |
4 | TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 25 | 328 | 4.006e-09 | 9.304e-07 |
5 | TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION REGULATORY REGION SEQUENCE SPECIFIC BINDING | 22 | 315 | 1.629e-07 | 3.027e-05 |
6 | DOUBLE STRANDED DNA BINDING | 36 | 764 | 4.979e-07 | 7.71e-05 |
7 | MACROMOLECULAR COMPLEX BINDING | 53 | 1399 | 9.739e-07 | 0.0001292 |
8 | TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 17 | 226 | 1.532e-06 | 0.0001779 |
9 | REGULATORY REGION NUCLEIC ACID BINDING | 36 | 818 | 2.433e-06 | 0.0002347 |
10 | TRANSCRIPTION FACTOR ACTIVITY PROTEIN BINDING | 29 | 588 | 2.779e-06 | 0.0002347 |
11 | TRANSCRIPTION FACTOR BINDING | 27 | 524 | 2.754e-06 | 0.0002347 |
12 | GUANYL NUCLEOTIDE EXCHANGE FACTOR ACTIVITY | 19 | 303 | 5.58e-06 | 0.0004319 |
13 | TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION FACTOR BINDING | 12 | 133 | 8.59e-06 | 0.0005788 |
14 | PROTEIN DOMAIN SPECIFIC BINDING | 29 | 624 | 8.723e-06 | 0.0005788 |
15 | ENZYME BINDING | 58 | 1737 | 1.443e-05 | 0.000894 |
16 | PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY | 6 | 30 | 1.772e-05 | 0.001029 |
17 | MOLECULAR FUNCTION REGULATOR | 48 | 1353 | 1.908e-05 | 0.001042 |
18 | X14 3 3 PROTEIN BINDING | 5 | 19 | 2.195e-05 | 0.001133 |
19 | RNA POLYMERASE II TRANSCRIPTION FACTOR BINDING | 10 | 104 | 2.784e-05 | 0.001361 |
20 | PHOSPHATIDYLSERINE BINDING | 6 | 33 | 3.151e-05 | 0.001463 |
21 | RAS GUANYL NUCLEOTIDE EXCHANGE FACTOR ACTIVITY | 14 | 228 | 0.0001187 | 0.005252 |
22 | PHOSPHOLIPID BINDING | 18 | 360 | 0.0001858 | 0.007847 |
23 | KINASE BINDING | 25 | 606 | 0.0002383 | 0.00942 |
24 | MODIFIED AMINO ACID BINDING | 7 | 66 | 0.0002434 | 0.00942 |
25 | CORE PROMOTER PROXIMAL REGION DNA BINDING | 18 | 371 | 0.0002681 | 0.009964 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | NEURON PROJECTION | 49 | 942 | 1.302e-10 | 7.606e-08 |
2 | NEURON PART | 55 | 1265 | 6.13e-09 | 1.79e-06 |
3 | CELL PROJECTION | 66 | 1786 | 9.068e-08 | 1.765e-05 |
4 | CELL JUNCTION | 48 | 1151 | 2.212e-07 | 3.23e-05 |
5 | AXON | 25 | 418 | 4.481e-07 | 5.234e-05 |
6 | SOMATODENDRITIC COMPARTMENT | 31 | 650 | 2.502e-06 | 0.0002435 |
7 | EXCITATORY SYNAPSE | 15 | 197 | 5.449e-06 | 0.0004546 |
8 | SYNAPSE | 33 | 754 | 7.31e-06 | 0.0005336 |
9 | CYTOPLASMIC REGION | 17 | 287 | 3.581e-05 | 0.002323 |
10 | CELL CORTEX | 15 | 238 | 5.084e-05 | 0.002814 |
11 | DENDRITE | 22 | 451 | 5.3e-05 | 0.002814 |
12 | NEURONAL POSTSYNAPTIC DENSITY | 7 | 53 | 5.943e-05 | 0.002892 |
13 | CELL BODY | 23 | 494 | 7.305e-05 | 0.003282 |
14 | POSTSYNAPSE | 19 | 378 | 0.0001157 | 0.004814 |
15 | CELL PROJECTION PART | 35 | 946 | 0.0001236 | 0.004814 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | Hippo_signaling_pathway_hsa04390 | 11 | 154 | 0.0001714 | 0.00499 | |
2 | Hippo_signaling_pathway_multiple_species_hsa04392 | 5 | 29 | 0.0001919 | 0.00499 | |
3 | Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 | 10 | 139 | 0.0003172 | 0.005255 | |
4 | cAMP_signaling_pathway_hsa04024 | 12 | 198 | 0.0004043 | 0.005255 | |
5 | cGMP_PKG_signaling_pathway_hsa04022 | 10 | 163 | 0.001101 | 0.01039 | |
6 | Apelin_signaling_pathway_hsa04371 | 9 | 137 | 0.001199 | 0.01039 | |
7 | Oocyte_meiosis_hsa04114 | 8 | 124 | 0.002484 | 0.01845 | |
8 | ECM_receptor_interaction_hsa04512 | 5 | 82 | 0.01959 | 0.118 | |
9 | Cell_adhesion_molecules_.CAMs._hsa04514 | 7 | 145 | 0.02047 | 0.118 | |
10 | Calcium_signaling_pathway_hsa04020 | 8 | 182 | 0.0227 | 0.118 | |
11 | Gap_junction_hsa04540 | 5 | 88 | 0.02569 | 0.1214 | |
12 | Neuroactive_ligand_receptor_interaction_hsa04080 | 10 | 278 | 0.03932 | 0.1582 | |
13 | FoxO_signaling_pathway_hsa04068 | 6 | 132 | 0.03955 | 0.1582 | |
14 | Wnt_signaling_pathway_hsa04310 | 6 | 146 | 0.05913 | 0.2196 | |
15 | Focal_adhesion_hsa04510 | 7 | 199 | 0.08431 | 0.2923 | |
16 | Regulation_of_actin_cytoskeleton_hsa04810 | 7 | 208 | 0.1005 | 0.3268 | |
17 | p53_signaling_pathway_hsa04115 | 3 | 68 | 0.1376 | 0.421 | |
18 | TNF_signaling_pathway_hsa04668 | 4 | 108 | 0.1482 | 0.4281 | |
19 | mTOR_signaling_pathway_hsa04150 | 5 | 151 | 0.1584 | 0.4334 | |
20 | Sphingolipid_signaling_pathway_hsa04071 | 4 | 118 | 0.1847 | 0.4636 | |
21 | Rap1_signaling_pathway_hsa04015 | 6 | 206 | 0.1959 | 0.4636 | |
22 | AMPK_signaling_pathway_hsa04152 | 4 | 121 | 0.1962 | 0.4636 | |
23 | TGF_beta_signaling_pathway_hsa04350 | 3 | 84 | 0.2122 | 0.4797 | |
24 | Phosphatidylinositol_signaling_system_hsa04070 | 3 | 99 | 0.288 | 0.6205 | |
25 | Phospholipase_D_signaling_pathway_hsa04072 | 4 | 146 | 0.2983 | 0.6205 | |
26 | Mitophagy_animal_hsa04137 | 2 | 65 | 0.3486 | 0.6716 | |
27 | PI3K_Akt_signaling_pathway_hsa04151 | 8 | 352 | 0.3487 | 0.6716 | |
28 | Tight_junction_hsa04530 | 4 | 170 | 0.401 | 0.7447 | |
29 | Autophagy_animal_hsa04140 | 3 | 128 | 0.4367 | 0.783 | |
30 | ErbB_signaling_pathway_hsa04012 | 2 | 85 | 0.4794 | 0.7974 | |
31 | Apoptosis_hsa04210 | 3 | 138 | 0.4856 | 0.7974 | |
32 | Endocytosis_hsa04144 | 5 | 244 | 0.4907 | 0.7974 | |
33 | Phagosome_hsa04145 | 3 | 152 | 0.5504 | 0.8671 | |
34 | Cellular_senescence_hsa04218 | 3 | 160 | 0.5852 | 0.8671 | |
35 | MAPK_signaling_pathway_hsa04010 | 5 | 295 | 0.6582 | 0.925 | |
36 | Cell_cycle_hsa04110 | 2 | 124 | 0.6829 | 0.9345 | |
37 | Jak_STAT_signaling_pathway_hsa04630 | 2 | 162 | 0.8139 | 1 | |
38 | Ras_signaling_pathway_hsa04014 | 3 | 232 | 0.8174 | 1 |